No Evidence Found Between Weight-Loss Drugs & Suicidal Thoughts, Says EU
Europe’s top drug regulator has given a green light 🟢 to popular weight-loss and diabetes medications like Wegovy and Ozempic, concluding there’s no proven link to suicidal thoughts after a 9-month investigation. The decision comes as a relief to millions relying on these treatments globally.
The Big Break for Big Pharma
Shares of Novo Nordisk, maker of Wegovy and Ozempic, jumped 2% after the European Medicines Agency (EMA) dismissed safety concerns. The review analyzed data from U.S. studies and healthcare records, finding no direct connection between semaglutide (the active ingredient) and mental health risks. 💡
Why It Matters
These GLP-1 receptor agonists have become a pop-culture phenomenon 🎬, with celebrities and influencers touting their weight-loss benefits. But recent reports from Iceland had raised red flags. Now, experts like Dr. Robert Kushner of Northwestern University say the findings should reassure patients: \"Two major regulators agree—these drugs aren’t tied to suicidal behavior.\"
What’s Next for GLP-1 Drugs?
While the EMA and U.S. FDA have cleared the air, the UK’s health agency continues its review. Novo Nordisk and Eli Lilly (maker of Mounjaro) are still monitoring side effects, emphasizing patient safety. 🩺 Pro tip: Always consult your doctor if you experience mood changes while on medication!
